MPR Weekly Dose Podcast: Episode 12

This week we talk about the possible NDMA in ranitidine products; Approval of a new flu vaccine; The return of an antiarrhythmic agent; A new treatment for H. pylori infection; and the risk of biotin interference in test results that could lead to missed diagnoses.

MPR Weekly Dose Podcast: Episode 7

This week we talk about the new Invokana approval; The ranitidine recalls that led CVS to suspend all sales; The 11 serious cybersecurity vulnerabilities identified by the FDA that could affect medical devices and hospital networks; Entresto’s expanded indication; and the investigative COPD treatment that was rejected.

CVS Suspends Sale of Zantac, OTC Generic as More Ranitidine Recalls Announced

The Food and Drug Administration (FDA) is alerting healthcare professionals and patients of a voluntary recall of over-the-counter (OTC) ranitidine tablets 75mg and 150mg (all pack sizes and formats) manufactured by Apotex Corp. and labeled by Walgreens, Walmart, and Rite-Aid due to the presence of the probable human carcinogen, N-nitrosodimethylamine (NDMA), at low levels. Additionally,…